Evidence map›Paper›PMID 42034870›Full record

ArticleDiscover oncology2026

Construction of an efferocytosis related signature to predict the prognosis of pancreatic ductal adenocarcinoma.

Juan Li, Zhiwei Du, Xuxu Liu, Ti Pan, Yi Zheng, Yuanhang He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Juan LiDepartment of Operating Room, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Zhiwei DuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, 23 You Zheng Street, Harbin, 150001, Heilongjiang, China.
Xuxu LiuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, 23 You Zheng Street, Harbin, 150001, Heilongjiang, China.
Ti PanDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, 23 You Zheng Street, Harbin, 150001, Heilongjiang, China.
Yi ZhengDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, 23 You Zheng Street, Harbin, 150001, Heilongjiang, China.
Yuanhang HeDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, 23 You Zheng Street, Harbin, 150001, Heilongjiang, China. heyuanhang@hrbmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a poor prognosis. Efferocytosis can both promote and inhibit tumor progression, yet its role in PDAC remains largely unexplored.

methodsThe data were obtained from The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) databases. GeneMANIA was employed to construct the protein-protein interaction network. This study explored the relationship between efferocytosis-related genes and PDAC prognosis using survival analysis, mutation spectrum assessment, evaluation of the immune microenvironment (ssGSEA), and prediction of treatment response (TIDE).

resultsEighteen efferocytosis-related genes were highly expressed in PDAC, and their mutations were associated with poorer patient survival. Notably, high expression of key genes such as AGER, STAB2, and ICAM3 was linked to better overall survival (OS) and progression-free survival (PFS), whereas elevated expression of AXL and HAVCR1 predicted a worse prognosis. Based on these findings, a prognostic signature (EFR-Signature) was developed that can independently predict patient outcomes. Patients classified as low-risk exhibited stronger antitumor immune activity and greater sensitivity to immunotherapy.

conclusionsHAVCR1, AGER, AXL, STAB2, and ICAM3 are closely associated with the prognosis of PDAC. A prognostic signature based on these genes can serve as an independent predictor of patient outcomes.

Indexed as

BiomarkerEfferocytosisPancreatic ductal adenocarcinomaPrognosisSignature

Identifiers

PMID42034870
PMCPMC13247032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.